Recent insights suggest that combining suPAR levels with the detection of nephrin (76) or CD40 autoantibodies (77) in patients with focal segmental glomerulosclerosis (FSGS) could be particularly valuable, aiming to develop a kidney disease–specific composite scoring system. Here, CD40 is linked to focal segmental glomerulosclerosis.